0.273

2.34% -0.009

Aptevo Therapeutics Inc (APVO)

Overview News Price History Financials Discussions Forecast Stock Split

Aptevo Therapeutics Inc stock is traded at $0.273, with a volume of 733.89K. It is down -2.34% in the last 24 hours and up +62.86% over the past month. Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Previous Close:

$0.282

Open:

$0.285

24h Volume:

733.89K

Relative Volume:

0.12

Market Cap:

$3.54M

Revenue:

$12.99M

Net Income/Loss:

$-17.41M

P/E Ratio:

-0.083

EPS:

-3.29

Net Cash Flow:

$-11.73M

1W Performance:

-9.41%

1M Performance:

+62.86%

6M Performance:

-72.15%

1Y Performance:

-97.59%

1-Day Range:

$0.252

$0.2858

1-Week Range:

$0.2422

$0.3085

52-Week Range:

$0.138

$11.62

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name

Aptevo Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

206-838-0500

Address

2401 4TH AVE., SEATTLE, WA

Employee

Twitter

@aptevo

Next Earnings Date

2024-11-12

Latest SEC Filings

APVO's Discussions on Twitter

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight

Aptevo Therapeutics Inc Stock (APVO) Latest News

Oct 31, 2024

Aptevo Therapeutics Inc (NASDAQ: APVO) Has Great Upside Potential - Stocks Register

Oct 31, 2024

Oct 30, 2024

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

Oct 30, 2024

Oct 29, 2024

Alligator Bioscience presents positive interim data from Phase 1 study - Marketscreener.com

Oct 29, 2024

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - AccessWire

Oct 29, 2024

Oct 26, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World

Oct 26, 2024

Aptevo Therapeutics secures shareholder nod for key proposals By Investing.com - Investing.com South Africa

Oct 26, 2024

Oct 25, 2024

Aptevo Therapeutics secures shareholder nod for key proposals - Investing.com India

Oct 25, 2024

Oct 15, 2024

There is no doubt that Aptevo Therapeutics Inc (APVO) ticks all the boxes. - SETE News

Oct 15, 2024

Oct 14, 2024

Aptevo Therapeutics Inc (NASDAQ: APVO) – An Analysis Is What You Need - Stocks Register

Oct 14, 2024

Stock Market Recap: Aptevo Therapeutics Inc (APVO) Concludes at 0.15, a -2.87 Surge/Decline - The Dwinnex

Oct 14, 2024

A stock that deserves closer examination: Aptevo Therapeutics Inc (APVO) - US Post News

Oct 14, 2024

Oct 12, 2024

APVO stock plunges to 52-week low of $0.14 amid market challenges - Investing.com Australia

Oct 12, 2024

APVO stock plunges to 52-week low of $0.14 amid market challenges By Investing.com - Investing.com South Africa

Oct 12, 2024

Oct 11, 2024

You might want to take a look at Aptevo Therapeutics Inc (APVO) now - SETE News

Oct 11, 2024

Oct 09, 2024

APVO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 09, 2024

Oct 08, 2024

Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex

Oct 08, 2024